COVID-19: Development of novel algorithm-driven digital platform for assessing the Leukocyte ImmunoTest(TM) as a clinical parameter in monitoring vulnerability to coronavirus

COVID-19：开发新型算法驱动的数字平台，用于评估白细胞免疫测试（TM）作为监测冠状病毒脆弱性的临床参数

• 批准号: 56969
• 金额: $ 9.54万
• 依托单位: OXFORD MEDISTRESS LTD
• 依托单位国家: 英国
• 项目类别: Feasibility Studies
• 财政年份: 2020
• 资助国家: 英国
• 起止时间: 2020 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=56969
• 关键词: COVID; 19; Development; novel; algorithm

Oxford MediStress is developing the advanced Leukocyte ImmunoTest (LIT)(tm) as a rapid (10-minute) fingerprick in vitro blood test to assess how well an individual's immune system is functioning. In previous studies involving patients with a variety of cancers, we have demonstrated the clinical potential of the technique. Results from the recent FORECAST clinical trial at UCLH showed strong correlation between the LIT score and eventual clinical outcome for 70 prostate cancer patients. Recently, OMS has been invited to participate in a COVID-19 study on health care workers and critically-ill coronavirus patients at a London research hospital. In that study the team hopes to demonstrate the potential for the technique for providing an early-warning indicator of poor immune function for frontline NHS healthcare workers in order to determine who is at greatest risk of contracting coronavirus. Eventually, the technique could be used in many other facets of COVID-19 treatment and clinical research, including providing a new and useful clinical parameter for monitoring COVID-19 patients in intensive care, providing a new clinical parameter for assessing immune status for use in developing new COVID-19 vaccines and therapies, and assessing impact of PTSD (which causes immunosuppression) on healthcare workers after the initial pandemic has passed.In this project the team will develop a novel digital platform to support data analysis. The platform will enable individual assessment of risk/vulnerability based on a number of clinical parameters including the new clinical parameter (LIT) which we have developed. We will develop new mathematical tools and a new smartphone app as part of the project.In the project extension, following discussions with clinical experts, the team will extend its clinical study to assess neutrophil function using LIT in patients severely ill with COVID-19, and in particular will monitor those in ICU, to determine whether LIT score can provide a new prognostic indication of likely disease severity. The team already has ethics approval for conducting such a study in Birmingham. The key benefit of this project for the general public is the development of a new rapid test for assessing the strength of an individual's immune system and for monitoring patients severely ill with COVID-19.

牛津大麻正在开发晚期白细胞免疫（LIT）（TM），作为一种快速（10分钟）的体外血液测试指纹，以评估个人的免疫系统的正常运行状况。在以前涉及各种癌症患者的研究中，我们证明了该技术的临床潜力。最近在UCLH进行的预测临床试验的结果显示，70名前列腺癌患者的LIT评分与最终的临床结果之间的相关性很强。最近，OMS被邀请参加伦敦一家研究医院的COVID-19-19-COVID-19-COVID-19S研究。在该研究中，小组希望证明该技术的潜力是为前线NHS医疗保健工人提供不良免疫功能的早期指标，以确定谁是签发冠状病毒的最大风险。最终，该技术可以用于COVID-19治疗和临床研究的许多其他方面，包括提供一个新的且有用的临床参数，用于监测重症监护中的Covid-19患者，为评估用于评估免疫状态的新临床参数用于用于使用在最初的大流行通过后，开发新的COVID-19疫苗和疗法，并评估PTSD（导致免疫抑制）对医疗保健工人的影响。在该项目中，该团队将开发一个新颖的数字平台来支持数据分析。该平台将基于许多临床参数（包括我们开发的新临床参数（LIT））对风险/脆弱性进行个人评估。我们将开发新的数学工具和一个新的智能手机应用程序作为项目的一部分。在项目扩展中，在与临床专家进行了讨论之后，该团队将扩展其临床研究，以评估中性粒细胞功能，并使用Covid-19的患者严重生病，特别是将监测ICU中的人员，以确定点状得分是否可以提供可能疾病严重程度的新预后指示。该团队已经在伯明翰获得了这项研究的道德批准。该项目对公众的关键好处是开发了一种新的快速测试，以评估个人免疫系统的强度以及监测COVID-19的患者严重患者。